Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 12, 2010, Pages 1048-1055

  Rahier, Jean François ^a   Buche, Sébastien ^b   Peyrin Biroulet, Laurent ^c   Bouhnik, Yoram ^d   Duclos, Bernard ^e   Louis, Edouard ^f   Papay, Pavol ^g   Allez, Matthieu ^h   Cosnes, Jacques ⁱ   Cortot, Antoine ^b   Laharie, David ^j   Reimund, Jean Marie ^k   Lémann, Marc ^h   Delaporte, Emmanuel ^b   Colombel, Jean Frédéric ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d BEAUJON HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Dermatological Complications; Side Effects of Anti TNF Therapy; Skin Eruptions

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE SEVERITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSORIASIS; RECURRENT DISEASE; REMISSION; RISK FACTOR; SCALP; SKIN DEFECT; SKIN INFLAMMATION; ULCERATIVE COLITIS;

ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; PSORIASIS; RISK FACTORS; SKIN DISEASES, ECZEMATOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 78649713662     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.07.022     Document Type: Article

References (34)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the accent I randomised trial. Lancet 2002, 359:1541-1549.
2. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
3. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
4. Sands B.E., Blank M.A., Diamond R.H., et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the Accent II study. Aliment Pharmacol Ther 2006, 23:1127-1136.
5. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
6. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
7. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
8. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
9. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009, 20:100-108.
10. Smith C.H., Anstey A.V., Barker J.N., et al. British association of dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161:987-1019.
11. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19:210-216.
12. Flendrie M., Vissers W.H., Creemers M.C., et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666-R676.
13. Lee H.H., Song I.H., Friedrich M., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007, 156:486-491.
14. Harrison M.J., Dixon W.G., Watson K.D., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
15. Delaporte E. [Immune-mediated inflammatory diseases and psoriasis]. Ann Dermatol Venereol 2008, 135(Suppl 4):S269-S274.
16. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
17. Esmailzadeh A., Yousefi P., Farhi D., et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatol Basel Switzerland 2009, 219:263-267.
18. Wollina U., Hansel G., Koch A., et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
19. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780.
20. Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6:366-372.
21. Ho P., Bruce I.N., Silman A., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005, 52:3596-3602.
22. Hagforsen E., Awder M., Lefvert A.K., et al. Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?. Acta Derm Venereol 2002, 82:341-346.
23. Naldi L., Mercuri S.R. Smoking and psoriasis: from epidemiology to pathomechanisms. J Invest Dermatol 2009, 129:2741-2743.
24. Vissers W.H., Roelofzen J., De Jong E.M., et al. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol 2005, 15:13-17.
25. Avila Alvarez A., García-Alonso L., Solar Boga A., et al. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease [in Spanish]. An Pediatr (Barc) 2009, 70:278-281.
26. Peramiquel L., Puig L., Dalmau J., et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol 2005, 30:713-714.
27. Collamer A.N., Guerrero K.T., Henning J.S., et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
28. Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004, 63:755-758.
29. Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004, 51:534-542.
30. Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005, 152:1304-1312.
31. Palucka A.K., Blanck J.P., Bennett L., et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005, 102:3372-3377.
32. Nestle F.O., Conrad C., Tun-Kyi A., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
33. de Gannes G.C., Ghoreishi M., Pope J., et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143:223-231.
34. Seneschal J., Milpied B., Vergier B., et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009, 161:1081-1088.